ARK Genomic Revolution ETF
ARKG
ARK Genomic Revolution ETF ARKG Strategy
The investment seeks long-term growth of capital.
The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.
The investment objective & strategy is a summary of the investment's principal strategy as written in the prospectus. This information is pulled from the most recent product disclosure document.
ETFs News & Analysis
etfs
Young & Invested: Why we just downgraded one of the biggest ETFs on the ASX
Our new research methodology sees us turn Negative on this popular choice.
etfs
Under the hood of popular ETFs
Mark and Shani run through some of Australia’s most popular ETFs and the exposure you’re getting.
etfs
Young & Invested: Why we just downgraded this ETF you might own
A ratings shift that could matter for your portfolio.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,012.60 | 10.70 | 0.12% |
| CAC 40 | 8,385.49 | 44.78 | 0.54% |
| DAX 40 | 24,740.36 | 153.22 | -0.62% |
| Dow JONES (US) | 52,102.05 | 435.21 | 0.84% |
| FTSE 100 | 10,461.63 | 32.78 | 0.31% |
| HKSE | 23,412.18 | 75.90 | 0.33% |
| NASDAQ | 25,659.66 | 72.63 | 0.28% |
| Nikkei 225 | 69,174.97 | 613.41 | -0.88% |
| NZX 50 Index | 13,400.66 | 35.11 | -0.26% |
| S&P 500 | 7,392.74 | 27.28 | 0.37% |
| S&P/ASX 200 | 8,808.40 | 7.00 | 0.08% |
| SSE Composite Index | 4,110.81 | 4.56 | 0.11% |